Researchers have identified a potential new strategy for attacking prostate cancers that evade treatment by changing their cellular identity. In preclinical experiments, combining two types of drugs reversed many of these cellular changes and sharply slowed tumor growth, offering a possible path forward for aggressive, treatment-resistant disease.
The study, published by a team of scientists investigating advanced prostate cancer, focuses on tumors that stop responding to standard therapies. Rather than simply becoming resistant to a single drug, some cancer cells undergo a form of identity shift, altering their characteristics in ways that allow them to survive treatment and continue growing. This plasticity has been a major obstacle in managing the most difficult cases of the disease.
The researchers found that this cellular reprogramming could be countered by pairing two existing classes of drugs. When used together, the drug combination appeared to reverse many of the changes that allowed the cancer cells to evade treatment. In animal models, the approach significantly slowed tumor progression compared with either drug alone.
Prostate cancer is one of the most common cancers in men, and while many cases respond well to initial treatment, a subset becomes resistant over time. For these patients, options are limited, and the disease can become lethal. The new findings point to a mechanism that could be exploited to restore sensitivity to treatment or to attack the cancer through a different route.
The cellular identity changes observed in the study are part of a broader phenomenon known as lineage plasticity, in which cancer cells lose features of their original tissue type and take on characteristics of other cell types. This process has been linked to resistance in several cancers, including prostate and lung cancer. Understanding how to block or reverse this process is considered a promising area of oncology research.
While the results are encouraging, the work is still at the preclinical stage. The researchers emphasize that further studies are needed to determine whether the combination approach will be safe and effective in human patients. Clinical trials would be required before the strategy could become available as a treatment option.
The study adds to a growing body of research aimed at outsmarting treatment-resistant cancers by targeting the mechanisms they use to survive. If the approach holds up in human studies, it could eventually offer a new line of defense for patients with aggressive prostate cancer who currently have few options.
The findings were reported by the research team in a scientific publication, with details of the drug combination and its effects on tumor growth. The team plans to continue investigating the approach, including how it might be combined with other therapies or used in different stages of the disease.
